Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
about
Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics TechnologyThe G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity.Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicityEXPRESS: Methylcobalamin ameliorates neuropathic pain induced by vincristine in rats: Effect on loss of peripheral nerve fibers and imbalance of cytokines in the spinal dorsal horn.Drugging the pain epigenome.Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics.Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins.Ninjin'yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells.Presynaptic N-Methyl-d-aspartate (NMDA) Receptor Activity Is Increased Through Protein Kinase C in Paclitaxel-induced Neuropathic PainExcessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug.Circulating microRNA Signatures in Rodent Models of Pain.Quetiapine reverses paclitaxel-induced neuropathic pain in mice: Role of alpha2- adrenergic receptors.Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice.Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.Presynaptic mGluR5 receptor controls glutamatergic input through protein kinase C-NMDA receptors in paclitaxel-induced neuropathic pain.Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.α-Spinasterol: a COX inhibitor and a transient receptor potential vanilloid 1 antagonist presents an antinociceptive effect in clinically relevant models of pain in mice.Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension.A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy.Association of Interleukin-6 and Other Cytokines with Self-Reported Pain in Prostate Cancer Patients Receiving Chemotherapy.Sensitization of TRPV1 receptors by TNF-α orchestrates the development of vincristine-induced pain.The stress regulator FKBP51: a novel and promising druggable target for the treatment of persistent pain states across sexes.Neuroinflammation and Central Sensitization in Chronic and Widespread Pain.Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.Short-term incubation of gabapentin or pregabalin does not affect chemically induced injury in neuronal cell models in vitro.
P2860
Q28551798-3EA483DE-7A64-403C-8A67-AD15BA1705AFQ33672384-A722FCB8-0CBF-409F-BC78-946786D95FC9Q37044941-9EC8D021-BF5F-4C45-B85E-19B00F71E04FQ37114802-80D64E0F-A426-47FD-AA7E-74466B7D54C1Q38761806-8E19D989-1725-444D-AF37-2F4AA24E2C49Q39158236-9B9F903C-88C1-4F74-B4FE-37ED9D720B6BQ39187514-4A4DB482-0900-48DC-B60F-478F7B2D34FFQ40154379-191A6DED-C98F-403F-A491-751446FA14D6Q41049504-17C76B66-3BF4-471A-8BC9-97A1DAD1B979Q41547771-A9BDA5ED-305C-478A-9992-150D5037A18BQ45876878-C7C2B6C8-DDF0-4340-9DB8-45FC5BF40BF4Q47115156-0949E9F6-858A-4A39-BFF7-AEA0F39E1102Q47214245-1078C8C2-ACBB-4E79-B29E-ED3AE84AD601Q47266458-759D894C-781D-45B3-BA5F-9BC289DF2557Q47564629-5B35D991-66F2-42F3-84A3-049AF2068197Q47598158-A67516D0-6600-4580-AD6E-7A37432556D8Q47732599-6FECC221-6189-439C-924D-7C5E64897281Q48164902-A84053DE-4143-4652-AFCC-C7BE772F8F90Q48737325-EB722ED4-E7AF-489A-9E45-8B12B6AD797DQ49101922-DAC61830-3E97-4F24-AA9F-8F3331D2A946Q49520475-21EE565A-BE03-4BDC-B850-B444AFFDDDBEQ50089437-E277E186-DA3C-4E98-96D9-BBE19075DE0DQ52649743-201763DD-7B81-4FBE-A337-F4321A57DB11Q52658325-FC9D0B8C-88EB-404C-B8B2-7632B87CB078Q52692785-7A84A863-5E49-4B77-8E1B-D962D20950FAQ52693014-7534650B-6AD5-4719-B21F-46B784D73034Q53200053-6A0B9DD6-7021-40B3-B586-CE5EABE5389AQ55367606-243159B6-C1F8-4DA7-B937-B262731C2AD4
P2860
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
@en
type
label
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
@en
prefLabel
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
@en
P2093
P2860
P1476
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.
@en
P2093
Gerd Geisslinger
Klaus Scholich
Ralf Baron
P2860
P2888
P304
P356
10.1038/NRNEUROL.2014.211
P407
P577
2014-11-04T00:00:00Z
P5875
P6179
1053480488